Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 0.82 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | CDK8 | P49336 | 1/20 | 0.64 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426333 | 0.92 | MAPT (0.85) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17712418 | 0.92 | MAPT (0.85) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16384066 | 0.92 | MAPT (0.85) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL427966 | 0.89 | RAB9A (0.83) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL426701 | 0.89 | RAB9A (0.83) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL18537729 | 0.86 | MAPT (0.75) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL426591 | 0.85 | RAB9A (0.76) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL428775 | 0.84 | RAB9A (0.81) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12562440 | 0.84 | CDK8 (0.83) | MAPTTHRBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16384051 | 0.83 | RAB9A (1.00) | MAPTTHRBSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2014089378-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 138/4885THRB 440/4885SMN1; SMN2 993/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 85/4885THRB 396/4885SMN1; SMN2 1076/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | MAPT 85/4885THRB 396/4885SMN1; SMN2 1076/4885 |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | CD4, CCR5, MMP8 | MAPT 1713/4885THRB 4410/4885SMN1; SMN2 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.